Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Kumar Prabhash's publication output changed over time?
ScholarIQpublication output · 2012–2022
Output declined67% over the shown period — from 3 works in 2012 to 1 in 2022.
3
1
1
3
1
1
1
2012201320142017201920212022
What are the most-cited papers on Kumar Prabhash?
ScholarIQmost cited works
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Göksel, Keunchil Park, Vera Gorbunova, Rubén Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyżewicz, С. В. Орлов, C. Lewanski, Michael Thomas, Paolo Bidoli, Shaker R. Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, M. Pérol
The Lancet. 20141,312 CitationsOPEN ACCESS
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer
Vanita Noronha, Vijay Patil, Amit Joshi, Nandini Menon, Anuradha Chougule, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Rajiv Kumar, Sucheta More, Supriya Goud, Nandkumar Kadam, Nilesh Daware, Atanu Bhattacharjee, Srushti Shah, Akanksha Yadav, Vaishakhi Trivedi, Vichitra Behel, Amit Dutt, Shripad Banavali, Kumar Prabhash
Journal of Clinical Oncology. 2019424 Citations
Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study
Giorgio V. Scagliotti, Vera Hirsh, Salvatore Siena, David H. Henry, Penella J. Woll, Christian Manegold, Philippe Solal‐Céligny, Gladys Rodriguez, Maciej Krzakowski, Nilesh Mehta, Lara Lipton, José Á. García-Sáenz, José Rodrigues Pereira, Kumar Prabhash, Tudor–Eliade Ciuleanu, Vladimir Kanarev, Huei Wang, Arun Balakumaran, Ira Jacobs
Journal of Thoracic Oncology. 2012340 CitationsOPEN ACCESS
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
Vanita Noronha, Amit Joshi, Vijay Patil, Jaiprakash Agarwal, Sarbani Ghosh Laskar, Ashwini Budrukkar, Vedang Murthy, Tejpal Gupta, Anil D′Cruz, Shripad Banavali, Prathamesh Pai, Pankaj Chaturvedi, Devendra Chaukar, Nikhil Pande, Arun Chandrasekharan, Vikas Talreja, Dilip Harindran Vallathol, Vijayalakshmi Mathrudev, Aparna Manjrekar, Kamesh Maske, Arati Sanjay Bhelekar, Kavita Nawale, Sadhana Kannan, Vikram Gota, Atanu Bhattacharjee, Shubhada Kane, Shashikant Juvekar, Kumar Prabhash
Journal of Clinical Oncology. 2017340 Citations
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
Vedang Murthy, Priyamvada Maitre, Sadhana Kannan, Gitanjali Panigrahi, Rahul Krishnatry, Ganesh Bakshi, Gagan Prakash, Mahendra Pal, Santosh Menon, Reena Phurailatpam, Smruti Mokal, Dipika Chaurasiya, Palak Popat, Nilesh Sable, Archi Agarwal, Venkatesh Rangarajan, Amit Joshi, Vanita Noronha, Kumar Prabhash, Umesh Mahantshetty
Journal of Clinical Oncology. 2021334 Citations
Related on ScholarIQ
Homi Bhabha National Institute
Institution
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Paper
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i>-Mutated Lung Cancer
Paper
Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study
Paper
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial
Paper
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
Paper